Restricting benzodiazepines to short-term prescription

JAMA Psychiatry

Volumn 72, Issue 7, 2015, Pages 734-735

  Krystal, John H ^a,b,c   Stossel, Scott ^d   Krystal, Andrew D ^e,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d The Atlantic Philanthropies   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; TEMAZEPAM;

ANXIETY DISORDER; FOLLOW UP; GERIATRIC PATIENT; HUMAN; INSOMNIA; LETTER; PSYCHIATRIST; SLEEP; FEMALE; MALE; PRESCRIPTION; STATISTICS AND NUMERICAL DATA;

BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE;

EID: 84937468124     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0351     Document Type: Letter

References (6)

1. Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry. 2015;72(2):110-111.
2. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for US clinical practice. Sleep Med Rev. 2009;13(4):265-274.
3. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991-999.
4. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495.
5. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7): 793-799.
6. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5-year naturalistic follow-up study. Arch Gen Psychiatry. 1989;46(11): 993-999.